<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028717</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069122</org_study_id>
    <secondary_id>CKTO-2000-10</secondary_id>
    <secondary_id>HOVON-46NHL</secondary_id>
    <secondary_id>EU-20130</secondary_id>
    <secondary_id>HOVON-CKVO-2000-10</secondary_id>
    <nct_id>NCT00028717</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Commissie Voor Klinisch Toegepast Onderzoek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells
      and either kill them or deliver tumor-killing substances to them without harming normal
      cells. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. It
      is not yet known if combination chemotherapy plus filgrastim is more effective with or
      without rituximab in treating non-Hodgkin's lymphoma.

      PURPOSE: Randomized phase III trial to determine the effectiveness of combination
      chemotherapy plus filgrastim with or without rituximab in treating older patients who have
      non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP),
           and filgrastim (G-CSF) with or without rituximab on event-free survival of elderly
           patients with intermediate or high-risk non-Hodgkin's lymphoma.

        -  Compare the complete remission rate, overall survival, and disease-free survival of
           patients treated with these regimens.

        -  Compare the toxicity of these regimens in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center, WHO classification, and International Prognostic Index score. Patients
      are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day
           1; oral prednisone on days 1-5; and filgrastim (G-CSF) subcutaneously on days 1-14.
           Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or
           unacceptable toxicity.

        -  Arm II: Patients receive cyclophosphamide, doxorubicin, vincristine, prednisone, and
           G-CSF as in arm I. Patients also receive rituximab IV on day 3 of courses 1-2 and on day
           1 of courses 3-6 for a total of 6 doses.

      Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 400 patients (200 per treatment arm) will be accrued for this
      study within 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free interval</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-Hodgkin's lymphoma (NHL)

               -  Low- or high-intermediate or high-risk lymphoma of any of the following subtypes:

                    -  Mantle cell lymphoma

                    -  Follicular lymphoma (grade III)

                    -  Diffuse large B-cell lymphoma

          -  CD20-positive

          -  No suspected or documented CNS involvement by NHL NOTE: A new classification scheme
             for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of
             &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,
             &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former
             terminology.

        PATIENT CHARACTERISTICS:

        Age:

          -  65 and over

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin less than 1.75 mg/dL*

          -  Transaminases less than 2.5 times normal* NOTE: * Unless due to NHL

        Renal:

          -  Creatinine less than 1.7 mg/dL (unless due to NHL)

        Cardiovascular:

          -  No severe cardiac dysfunction

          -  No New York Heart Association class II-IV heart disease

          -  LVEF at least 45%

        Pulmonary:

          -  No uncontrolled asthma requiring steroid treatment

        Other:

          -  HIV negative

          -  No intolerance to exogenous protein administration

          -  No active, uncontrolled infection

          -  No uncontrolled allergy requiring steroid treatment

          -  No other malignancy within the past 5 years except basal cell skin cancer or stage 0
             cervical cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy for NHL

        Chemotherapy:

          -  No prior chemotherapy for NHL

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy for NHL except local radiotherapy for potential organ
             dysfunction by localized lymphoma mass or infiltration

          -  Concurrent local radiotherapy for potential or actual organ dysfunction by localized
             lymphoma mass or infiltration allowed

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter Sonneveld, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Daniel Den Hoed Cancer Center at Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HagaZiekenhuis - Locatie Leyenburg</name>
      <address>
        <city>'s-Gravenhage</city>
        <zip>2545 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <zip>3816 CP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum at University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <zip>7500 KA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 EZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken - locatie Sophia</name>
      <address>
        <city>Zwolle</city>
        <zip>8000 GK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

